<DOC>
	<DOCNO>NCT00745823</DOCNO>
	<brief_summary>A study evaluate safety , tolerability efficacy daily Raltegravir compare twice daily raltegravir give combination TRUVADA™ treatment-naïve human immunodeficiency virus ( HIV ) -infected patient .</brief_summary>
	<brief_title>A Study Determine Safety Efficacy Once Daily Raltegravir Compared Twice Daily Raltegravir ( MK-0518-071 )</brief_title>
	<detailed_description>Following 96-week double-blind study period ( MK0518-071 ) ( NCT00745823 ) , subject may enroll extension study ( MK0518-071-10 ) ( NCT00745823 ) . From week 96 120 , subject ' treatment assignment remain base study . From week 120 240 , subject receive open-label raltegravir ( 800 mg , daily ) combination TRUVADA™ .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient male female 18 year age old Patient HIV positive Patient naïve antiretroviral therapy ( ART ) receive less 7 day total ART Extension Study : The plan extension study take place study terminate Week 48 analysis . Patient user recreational illicit drug recent history ( within last year ) drug alcohol abuse dependence Patient document resistance tenofovir emtricitabine Patient currently participate participate study investigational compound device within 45 day sign informed consent Patient pregnant breastfeeding , expect conceive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV Infections</keyword>
	<keyword>Treatment Naïve</keyword>
</DOC>